Clinical trial
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
NCT05226923 is registered in ClinicalTrials.gov with Sumitovant Biopharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
- Lead sponsor
- Sumitovant Biopharma, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 12, 2022
- Completion date
- October 1, 2022
- Enrollment
- 123 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.